MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 140 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 1.07 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $225,648,303 | -36.8% | 1,545,113 | 0.0% | 1.30% | -37.1% |
Q2 2023 | $356,921,103 | -4.6% | 1,545,113 | 0.0% | 2.07% | +1.4% |
Q1 2023 | $374,319,075 | -16.5% | 1,545,113 | 0.0% | 2.04% | -24.4% |
Q4 2022 | $448,469,048 | +360.3% | 1,545,113 | +3.1% | 2.69% | +322.1% |
Q3 2022 | $97,434,000 | -9.2% | 1,499,213 | 0.0% | 0.64% | +4.8% |
Q2 2022 | $107,314,000 | -27.0% | 1,499,213 | 0.0% | 0.61% | -27.9% |
Q1 2022 | $147,103,000 | +15.8% | 1,499,213 | 0.0% | 0.84% | +36.7% |
Q4 2021 | $127,043,000 | +6.2% | 1,499,213 | 0.0% | 0.62% | +17.7% |
Q3 2021 | $119,622,000 | -18.1% | 1,499,213 | 0.0% | 0.52% | -18.1% |
Q2 2021 | $146,038,000 | -16.7% | 1,499,213 | 0.0% | 0.64% | -15.7% |
Q1 2021 | $175,363,000 | +5.2% | 1,499,213 | 0.0% | 0.76% | +21.0% |
Q4 2020 | $166,668,000 | -6.4% | 1,499,213 | 0.0% | 0.63% | -11.7% |
Q3 2020 | $178,002,000 | +4.8% | 1,499,213 | +0.0% | 0.71% | -5.1% |
Q2 2020 | $169,786,000 | +69.6% | 1,499,212 | 0.0% | 0.75% | +21.6% |
Q1 2020 | $100,087,000 | -6.1% | 1,499,212 | +28.2% | 0.62% | +8.8% |
Q4 2019 | $106,533,000 | +5.7% | 1,169,278 | 0.0% | 0.57% | -17.5% |
Q3 2019 | $100,815,000 | -17.7% | 1,169,278 | 0.0% | 0.69% | -17.6% |
Q2 2019 | $122,552,000 | -16.3% | 1,169,278 | 0.0% | 0.83% | -11.2% |
Q1 2019 | $146,464,000 | +11.1% | 1,169,278 | 0.0% | 0.94% | -13.1% |
Q4 2018 | $131,801,000 | -47.4% | 1,169,278 | 0.0% | 1.08% | -34.6% |
Q3 2018 | $250,377,000 | -23.4% | 1,169,278 | 0.0% | 1.65% | -32.9% |
Q2 2018 | $327,035,000 | +354.8% | 1,169,278 | +89.9% | 2.46% | +303.4% |
Q1 2018 | $71,906,000 | +27.2% | 615,684 | 0.0% | 0.61% | +24.3% |
Q4 2017 | $56,514,000 | +2075.3% | 615,684 | +965.9% | 0.49% | +2233.3% |
Q3 2017 | $2,598,000 | +176.7% | 57,762 | 0.0% | 0.02% | +162.5% |
Q2 2017 | $939,000 | +5.5% | 57,762 | 0.0% | 0.01% | +14.3% |
Q1 2017 | $890,000 | +3.4% | 57,762 | 0.0% | 0.01% | -12.5% |
Q4 2016 | $861,000 | +17.6% | 57,762 | 0.0% | 0.01% | +14.3% |
Q3 2016 | $732,000 | – | 57,762 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Avoro Capital Advisors LLC | 1,425,000 | $113,701,000 | 1.79% |
L1 Capital Pty Ltd | 164,860 | $13,154,000 | 1.64% |
ARMISTICE CAPITAL, LLC | 1,036,000 | $82,662,000 | 1.40% |
Tao Capital Management LP | 51,396 | $4,101,000 | 1.09% |
Parkman Healthcare Partners LLC | 31,393 | $2,505,000 | 0.63% |
Baker Brothers Advisors | 1,499,213 | $119,622,000 | 0.52% |
Rock Springs Capital Management LP | 262,500 | $20,945,000 | 0.44% |
ORACLE INVESTMENT MANAGEMENT INC | 38,500 | $3,072,000 | 0.38% |
Capital Impact Advisors, LLC | 11,775 | $940,000 | 0.37% |
Hennion & Walsh Asset Management, Inc. | 73,936 | $5,899,000 | 0.31% |